Description | Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease. |
In vivo | Crizanlizumab(1或6 mg/kg;腹腔注射;每周三次;持续5个月)在4周龄的雄性HbSS(镰状细胞病)小鼠中改善了镰状细胞视网膜病变[2]。 |
Synonyms | ADAKVEO, SEG-101 |
molecular weight | N/A |
CAS | 1690318-25-2 |
Storage | store at low temperature | store at -80°C |
References | 1. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020). 2. Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747. 3. Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. |